Viatris
VTRS · NYSE · Healthcare · United States
$17.23-2.1%
Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:40 PM
Ask MarketChacha about VTRS
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
In the news
- Viatris (VTRS) Draws Fresh Attention Following Pain Management Partnership And Undervalued Narrativesimplywall.st · 7/17/2026
- Biocon shares gain 6.5% after Viatris sells its stake in a block dealBusiness Standard · 7/14/2026
- Biocon shares jump 6% as Mylan likely exits drugmaker after Rs 3,481 crore stake saleThe Economic Times · 7/14/2026
- Viatris unit Mylan plans to sell stake worth up to $363 million in BioconBusiness Standard · 7/13/2026
- Should Value Investors Buy Viatris (VTRS) Stock?Yahoo Finance · 7/9/2026
- 3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now24/7 Wall St. · 7/7/2026
- Viatris (VTRS) Could Be 57% Undervalued As Phase 3 Kidney Data Landssimplywall.st · 7/3/2026
- Viatris (VTRS) director David S. Simmons granted 2,362 deferred stock units as feesStock Titan · 7/1/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.